BBHC
AGIO icon

Brown Brothers Harriman & Co’s Agios Pharmaceuticals AGIO Stock Holding History

Brown Brothers Harriman & Co’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-144
Closed -$3.92K – 1802
2025
Q4 		$3.92K Buy
+144
New +$5.05K ﹤0.01% 1582
2018
Q2 		– Sell
-30
Closed -$2K – 808
2018
Q1 		$2K Sell
30
-23
-43% -$1.78K ﹤0.01% 741
2017
Q4 		$3K Buy
+53
New +$3.33K ﹤0.01% 928

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Brown Brothers Harriman & Co's AGIO Position: Q1 2026 in Review

Brown Brothers Harriman & Co sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 144 shares — an estimated $3.92K sold.

Brown Brothers Harriman & Co first reported a position in AGIO in Q4 2017 and held it in 3 quarters. The position peaked at $3.92K in Q4 2025. 234 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Brown Brothers Harriman & Co reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 144 Agios Pharmaceuticals shares in Q1 2026, an estimated $3.92K.
  • Brown Brothers Harriman & Co first reported a position in Agios Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Brown Brothers Harriman & Co's Agios Pharmaceuticals position peaked at $3.92K in Q4 2025.
  • 234 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2026, filed 14 May 2026.